|
1
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
|
2
|
Takeuchi Y and Nishikawa H: Roles of
regulatory T cells in cancer immunity. Int Immunol. 28:401–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duell J, Dittrich M, Bedke T, Mueller T,
Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H
and Topp MS: Frequency of regulatory T cells determines the outcome
of the T-cell-engaging antibody blinatumomab in patients with
B-precursor ALL. Leukemia. 31:2181–2190. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Facciabene A, Peng X, Hagemann IS, Balint
K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L and
Coukos G: Tumour hypoxia promotes tolerance and angiogenesis via
CCL28 and T(reg) cells. Nature. 475:226–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang J, Yan J and Liu B: Targeting
VEGF/VEGFR to modulate antitumor immunity. Front Immunol.
9:9782018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aguayo A, Kantarjian H, Manshouri T, Gidel
C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, et
al: Angiogenesis in acute and chronic leukemias and myelodysplastic
syndromes. Blood. 96:2240–2245. 2000.PubMed/NCBI
|
|
9
|
Li X, Li D, Huang X, Zhou P, Shi Q, Zhang
B and Ju X: Helios expression in regulatory T cells promotes
immunosuppression, angiogenesis and the growth of leukemia cells in
pediatric acute lymphoblastic leukemia. Leukemia Res. 67:60–66.
2018. View Article : Google Scholar
|
|
10
|
Getnet D, Grosso JF, Goldberg MV, Harris
TJ, Yen HR, Bruno TC, Durham NM, Hipkiss EL, Pyle KJ, Wada S, et
al: A role for the transcription factor Helios in human
CD4(+)CD25(+) regulatory T cells. Mol Immunol. 47:1595–1600. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HJ, Barnitz RA, Kreslavsky T, Brown
FD, Moffett H, Lemieux ME, Kaygusuz Y, Meissner T, Holderried TA,
Chan S, et al: Stable inhibitory activity of regulatory T cells
requires the transcription factor Helios. Science. 350:334–339.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
D'Alessio FR, Zhong Q, Jenkins J,
Moldobaeva A and Wagner EM: Lung angiogenesis requires CD4(+)
forkhead homeobox protein-3(+) regulatory T cells. Am J Respir Cell
Mol Biol. 52:603–610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Woidacki K, Meyer N, Schumacher A,
Goldschmidt A, Maurer M and Zenclussen AC: Transfer of regulatory T
cells into abortion-prone mice promotes the expansion of uterine
masT cells and normalizes early pregnancy angiogenesis. Sci Rep.
5:139382015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyara M, Ito Y and Sakaguchi S: TREG-cell
therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol.
10:543–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Terme M, Pernot S, Marcheteau E, Sandoval
F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E
and Taieb J: VEGFA-VEGFR pathway blockade inhibits tumor-induced
regulatory T-cell proliferation in colorectal cancer. Cancer Res.
73:539–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yadav M, Louvet C, Davini D, Gardner JM,
Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM,
Head R, Kuster DJ, et al: Neuropilin-1 distinguishes natural and
inducible regulatory T cells among regulatory T cell subsets in
vivo. J Exp Med. 209:1713–1722, S1711-1719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leung OM, Li J, Li X, Chan VW, Yang KY, Ku
M, Ji L, Sun H, Waldmann H, Tian XY, et al: Regulatory T cells
promote apelin-Mediated sprouting angiogenesis in Type 2 diabetes.
Cell Rep. 24:1610–1626. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sia D, Alsinet C, Newell P and Villanueva
A: VEGF signaling in cancer treatment. Curr Pharm Des.
20:2834–2842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shibuya M: VEGF-VEGFR signals in health
and disease. Biomol Ther(Seoul). 22:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Terme M, Tartour E and Taieb J:
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced
proliferation of regulatory T cells in cancer. Oncoimmunology.
2:e251562013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Syed Khaja AS, Toor SM, El Salhat H, Ali
BR and Elkord E: Intratumoral foxP3(+)helios(+) regulatory T cells
upregulating immunosuppressive molecules are expanded in human
colorectal cancer. Front Immunol. 8:6192017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakagawa H, Sido JM, Reyes EE, Kiers V,
Cantor H and Kim HJ: Instability of Helios-deficient Tregs is
associated with conversion to a T-effector phenotype and enhanced
antitumor immunity. Proc Natl Acad Sci U S A. 113:6248–6253. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schneidawind D, Pierini A, Alvarez M, Pan
Y, Baker J, Buechele C, Luong RH, Meyer EH and Negrin RS: CD4+
invariant natural killer T cells protect from murine GVHD lethality
through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
Blood. 124:3320–3328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fialova A, Partlova S, Sojka L, Hromádková
H, Brtnický T, Fučíková J, Kocián P, Rob L, Bartůňková J and Spíšek
R: Dynamics of T-cell infiltration during the course of ovarian
cancer: The gradual shift from a Th17 effector cell response to a
predominant infiltration by regulatory T-cells. Int J Cancer.
132:1070–1079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumai T, Nagato T, Kobayashi H,
Komabayashi Y, Ueda S, Kishibe K, Ohkuri T, Takahara M, Celis E and
Harabuchi Y: CCL17 and CCL22/CCR4 signaling is a strong candidate
for novel targeted therapy against nasal natural killer/T-cell
lymphoma. Cancer Immunol Immunother. 64:697–705. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niens M, Visser L, Nolte IM, van der
Steege G, Diepstra A, Cordano P, Jarrett RF Te Meerman GJ, Poppema
S and van den Berg A: Serum chemokine levels in Hodgkin lymphoma
patients: Highly increased levels of CCL17 and CCL22. Br J
Haematol. 140:527–536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pere H, Montier Y, Bayry J,
Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel
P, Marcheteau E, et al: A CCR4 antagonist combined with vaccines
induces antigen-specific CD8+ T cells and tumor immunity against
self antigens. Blood. 118:4853–4862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bangham CR and Toulza F: Adult T cell
leukemia/lymphoma: FoxP3(+) cells and the cell-mediated immune
response to HTLV-1. Adv Cancer Res. 111:163–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brunstein CG, Miller JS, McKenna DH,
Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR,
MacMillan ML, Levine BL, et al: Umbilical cord blood-derived T
regulatory cells to prevent GVHD: Kinetics, toxicity profile, and
clinical effect. Blood. 127:1044–1051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seay HR, Putnam AL, Cserny J, Posgai AL,
Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, et
al: Expansion of human tregs from cryopreserved umbilical cord
blood for GMP-compliant autologous adoptive cell transfer therapy.
Mol Ther Methods Clin Dev. 4:178–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Theil A, Tuve S, Oelschlagel U, Maiwald A,
Döhler D, Oßmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, et
al: Adoptive transfer of allogeneic regulatory T cells into
patients with chronic graft-versus-host disease. Cytotherapy.
17:473–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brunstein CG, Miller JS, Cao Q, McKenna
DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH,
Rubinstein P, et al: Infusion of ex vivo expanded T regulatory
cells in adults transplanted with umbilical cord blood: Safety
profile and detection kinetics. Blood. 117:1061–1070. 2011.
View Article : Google Scholar : PubMed/NCBI
|
